紧急热线: +603 7620 7979 / +603 7787 2992
EN
中文
IDN
临床试验对于寶康医院的研究中心至关重要，因此该中心在2020年被晋升为卓越中心（COE）。
我们的患者、肿瘤学团队和研究团队在马来西亚的多项临床试验和促进多种肿瘤药物的上市方面做出了重要贡献。
在 2021年，我们被马来西亚临床研究机构认可为马来西亚领先的肿瘤学临床试验中心之一。
对齐马来西亚的全球临床研究愿景，我们致力于寻找更好的癌症治疗方法，帮助癌症患者。
我们的研究项目均获得马来西亚卫生部伦理委员会的批准，并遵守良好临床实践标准，优先考虑试验患者的道德考虑。
迄今为止，我们的肿瘤科团队已参与多项临床试验，包括比较不同化疗的疗效；对抑制剂的抵抗力；鼻咽癌的表观遗传变化；以及治疗晚期或转移性胃食管连接部腺癌等。
| No. | Clinical Trial | Status | Clinical Trial Gov |
|---|---|---|---|
| 1 | CAPItello-292 A Phase Ib/III, Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in hormone receptor-positive and human epidermal growth factor receptor 2-negative locally advanced, unresectable or metastatic breast cancer | Active (Recruiting) | Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestran |
| 2 | OPERA-01 A phase 3 randomized, open-label study of OP-1250 monotherapy vs SOC for the treatment of ER+, HER2- advanced or metastatic breast cancer following endocrine and CDK4/6 inhibitor therapy | Active (Recruiting) | Study of OP-1250 monotherapy vs SOC |
| 3 | Elegant Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence - A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT) | Active (Recruiting) | Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence |
| 4 | EPIK-B3 CBYL719H12301 (EPIK B3) - A Phase III, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation. | Closed | Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel |
| 5 | EPIK-B2 CBYL719G12301 (EPIK B2) – A two part, Phase III, multicenter, randomized (1:1), double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with transtuzumab and pertuzumab as maintenance therapy in patients with HER2-positive advanced breast cancer with a PIK3CA mutation. | Closed | Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Trastuzumab |
| 6 | lidERA A phase III, randomized, open-label, multicenter study evaluating the efficacy and safety of adjuvant giredestrant compared with physician's choice of adjuvant endocrine monotherapy in patients with estrogen receptor-positive, her2-negative early breast cancer | Closed | Study Evaluating the Efficacy |
| 7 | TENOR Phase II Study to assess the efficacy of Talazoparib in asian mEtastatic breast caNcer patients with a hOmologous Recombinant deficiency (HRD) signature (TENOR) | Closed | NA |
| No | Clinical Trial | Status | Clinical Trial Gov |
|---|---|---|---|
| 1 | SOHO-02 A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non- small cell lung cancer (NSCLC) with HER2-activating mutations. | Active (Recruiting) | A Study to Learn More About How Well BAY 2927088 Works |
| 2 | ATORG001 A prospective, molecular profiling study of mutational genes in Asian patients with Non-Small Cell Lung Cancer. (Non-interventional study). | Active (Recruiting) | Study of mutational genes in Asian patients |
| 3 | ATORG004 Plasma Molecular Profiling in ALK inhibitor resistant non-small cell lung cancer | Active (Recruiting) | Plasma Molecular Profiling in ALK inhibitor resistant non-small cell lung cancer |
| 4 | PACIFIC-8 A Phase 3, Randomised, Double blind, Placebo controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum based Concurrent Chemoradiation Therapy (PACIFIC-8) | Active (Recruiting) | Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced |
| 5 | MK3475-D46 Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% | Active (Recruiting) | Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan |
| 6 | Paloma-2 A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer | Active (Recruiting) | Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors |
| 7 | Tropion Lung-15 A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants with EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer whose Disease has Progressed on Prior Osimertinib Treatment (TROPION-Lung15)r | Active (Recruiting) | Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
| 8 | BGB-LC-201 A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer | Closed | Study of Tislelizumab in Combination With Investigational Agents |
| 9 | Jimmy Lung A randomized, double-blind, parallel-group study to compare efficacy, safety, and immunogenicity of GME751 (proposed pembrolizumab biosimilar) and EU-authorized Keytruda® in adult participants with untreated metastatic non-squamous non-small cell lung cancer (NSCLC) | Closed | A Study to compare efficacy, safety, and immunogenicity of GME751 |
| 10 | INSIGHT-2A Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior osimertinib therapy | Closed | Study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) |
| 11 | LAURA A Phase III, randomized, double-blind, placebo-controlled, multicenter, international study of osimertinib as maintenance therapy in patients with locally advanced, unresectable EGFR mutation-positive on-Small Cell Lung Cancer (Stage III) whose disease has not progressed following definitive platinum-based chemoradiation therapy. | Closed | Study of osimertinib as maintenance therapy in patients with locally advanced |
| 12 | MARIPOSA A Randomized Study of JNJ-61186372 and Lazertinib Combination Therapy Versus Single Agent Osimertinib or Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer. | Closed | Study of JNJ-61186372 and Lazertinib Combination Therapy Versus Single Agent Osimertinib or Lazertinib as First-Line Treatment |
| 13 | ATORG003 A single-arm, open-label, phase 2 study of Dacomitinib with or without dose titration for the first-line treatment of locally advanced or metastatic non-small cell lung cancer in subjects with an epidermal growth factor receptor (egfr) activation mutation | Closed | Study of Dacomitinib with or without dose titration for the first-line treatment of locally advanced |
| 14 | ML41262 A Prospective, Multicentre, Genomic Profiling Study In Patients With Locally Advanced Or Metastatic Non-small Cell Lung Cancer (NSCLC) In Malaysia Using Foundation Medicine | Closed | - |
| 15 | INCMGA 0012-304 A Randomized, Double Blind, Phase 3 Study of Platinum-based Chemotherapy with or without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer Participants | Closed | Study of Platinum-based Chemotherapy with or without INCMGA00012 |
| 16 | PFIZER A7471067 Real-world utilization and outcomes with “study drug” first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer among Asian patients – A multi-center chart review | Closed | Real-world utilization and outcomes with “study drug” first-line treatment |
| 17 | MK7684A-002 A Phase II, multicenter, randomized study to compare the efficacy and safety of MK-7684A or MK-7684A plus Docetaxel versus Docetaxel monotherapy in the treatment of participants with metastatic non-small cell lung cancer with progressive disease after treatment with a platinum doublet chemotherapy and immunotherapy | Closed | Study to compare the efficacy and safety of MK-7684A or MK-7684A plus Docetaxel |
| 18 | MARIPOSA2 A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure | Closed | A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy |
| 19 | ADAURA-2 D516FC00001 - A Phase III, Double-blind, Randomized, Placebo-Controlled, International Study to assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Patients with EGFR mutation-positive, Stage IA2-IA3 Non-small Cell Lung Cancer, following Complete Tumor Resection | Closed | Study to assess the Efficacy and Safety of Adjuvant Osimertinib |
| 20 | kontRASt-02 CJDQ443B12301 : A randomized, controlled, open label, phase III study evaluating the efficacy and safety of JDQ443 versus docetaxel in previously treated subjects with locally advanced or metastatic KRAS G12C mutant non-small cell lung cancer | Closed | A randomized, controlled, open label, phase III study evaluating the efficacy and safety of JDQ443 |
| No | Clinical Trial | Status | Clinical Trial Gov |
|---|---|---|---|
| 1 | MO42541A phase III, open-label, randomized study of atezolizumab with lenvatinib or sorafenib versus lenvatinib or sorafenib alone in HCC previously treated with atezolizumab and bevacizumab | Closed | Study of atezolizumab with lenvatinib or sorafenib |
| No | Clinical Trial | Status | Clinical Trial Gov |
|---|---|---|---|
| 1 | Origami-1A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer | Closed | Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy |
| 2 | MK4280A-007A Phase 3 study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PD-L1 positive Colorectal Cancer | Closed | Study of atezolizumab with lenvatinib or sorafenib |
| 3 | Krystal-10A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy | Closed | Study of MRTX849 in Combination with Cetuximab |
| No | Clinical Trial | Status | Clinical Trial Gov |
|---|---|---|---|
| 1 | PRL3-ZumabAn Open Label, Multicenter, Safety and Efficacy Phase II/III Study of PRL3-Zumab in Solid Tumors Patients | Closed | NA |
| No | Clinical Trial | Status | Clinical Trial Gov |
|---|---|---|---|
| 1 | GCT3014-01An Open-Label, Multicenter, Phase 1/2 Study of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies | Closed | Study of GEN3014 (HexaBody®-CD38) |
| 2 | IMR BortezomibGenetic Variation Associated with Bortezomib Induced Peripheral Neuropathy in Adult Multiple Myeloma Patients (Investigator initiated study) | Closed | NA |
| No | Clinical Trial | Status | Clinical Trial Gov |
|---|---|---|---|
| 1 | CAAA617D12302An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617) versus Observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen (PSMA) positive Oligometastatic Prostate Cancer (OMPC) | Active (Recruiting) | An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC |
除了肿瘤学临床试验，来自其他卓越中心的顾问也通过发表研究论文为临床专业做出了重大贡献。以下是我们的顾问发表的研究成果（摘要、研究论文、海报等）:
| No | Publication Title | Name of Consultant | Type of Presentation |
|---|---|---|---|
| 1 | Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial | Dr Tho Lye Mun (Consultant Clinical Oncologist) | Original Article |
| 2 | Effectiveness of adjunctive ultrasound after mammography in improving breast cancer screening findings from a study in Malaysian women | Mohamed Ibrahim Wahid, Nurul Alia Azmi, Pei Yun Tan, Bao Jing Chen, | Original Article |
| 3 | Topical nonsteroidal anti‐inflammatory drugs for management of osteoarthritis pain: A consensus recommendation | Joon-Kiong Lee, Azlina A.Abbas, Tien-Eang Cheah, Ruslan Nazaruddin Simanjuntak, Sargunan Sockalingam, Sharifah Roohi | Original Article |
| 4 | Retrospective Analysis of Clinical Outcomes of Stereotactic Body Radiation Therapy for Localized Prostate Cancer at an Asian Cancer Specialist Centre | Jasmin Loh Pei Yuin, Jessica Tan Jia Shin, Chen Bao Jing, Tho Lye Mun, Manivanna Arkonam Balasubramaniam, Dato Mohamed Ibrahim Wahid | Original Article |
| 5 | KASRPImpact of a digital educational program on nurses’ knowledge and attitudes toward pain assessment and management in a Malaysian hospital. | Dr Koon Sim Lan Jessica Tan Jia Shin, Ph.D ( Clinical Informatics Specialist) | |
| 6 | Presenting complaints of patients and palliative care referral patterns | Dr Felicia Chang Dr Azura Jessica Tan Jia Shin, Ph.D (Clinical Informatics Specialist) | |
| 7 | Breast cancer survivorship in an Asian specialist centre from Malaysia: A retrospective analysis | Dato Ibrahim Dr Azura Arkonam Balasubramaniam Manivannan (Consultant Oncologists) Jessica Tan Jia Shin. Ph. D (Clinical Informatics Specialist) | Original Article |
| 8 | Does A Picture Really Paint A Thousand Words? A Study On The Technical Qualities Of Online Aesthetic Oculofacial Clinical Photographs | Dr Ong Chin Tuan (Consultant Ophthalmologist) | Poster |
| 9 | Healthcare Performance Measurement And Reporting For Breast Cancer Services in Malaysia | ||
| 10 | Healthcare Performance Measurement And Reporting System (HPMRS) For Cancer Care |
如果您有兴趣并想了解更多关于这些正在进行的试验，请通过+603-7787 2830 与我们联系，或者您可以给我们发邮件 clinicalresearch@beaconhospital.com.my.
| Member (Title and Name) | Occupation (Designation) | Male/Female (M/F) |
|---|---|---|
| Chairperson: Dr. Tho Lye Mun | Consultant Clinical Oncologist, Beacon Hospital | Male |
| Deputy Chairman: Dato’ Dr Lee Joon Kiong | Deputy Medical Director, Consultant Orthopaedic Surgeon, Beacon Hospital | Male |
| Secretary (non-voting): R Suntari Ramachandran | Assistant Manager, Clinical Research, Beacon Hospital | Female |
| Secretary (non-voting): Grace Kong Kah Yi | Clinical Research Coordinator, Beacon Hospital | Female |
| (Scientific / Medical) Dato' Dr Anuar Zaini Md Zain | Professor of Internal Medicine at Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Consultant Endocrinologist, Beacon Hospital | Male |
| (Scientific / Medical) Dr. Leong Kok Weng | Consultant Anaesthesiologist, Beacon Hospital | Male |
| (Scientific / Medical) Dr. Tengku Ahmad Hidayat | Consultant Hematologist, Beacon Hospital | Male |
| (Scientific / Medical) Dr. Koon Sim Lan | Consultant Palliative Medicine, Beacon Hospital | Female |
| (Non-Scientific / Medical) Wong Mei Teng | Manager of Medical Services Development Department | Female |
| (Non-Scientific / Non-Medical) Helen Wong | Legal Representative | Female |
| (Scientific / Non-Medical) Quah Sean I | Representative of Head, Department of Pharmacy | Female |
| (Non-Scientific / Non-Medical) Yong Lee Lee | Public Representative | Female |
| Month | Meeting Date (subject to change) | Submission Date |
|---|---|---|
| January | 23 January 2026 | 9 January 2026 |
| February | 27 February 2026 | 13 February 2026 |
| March | 20 March 2026 | 6 March 2026 |
| April | 24 April 2026 | 10 April 2026 |
| May | 22 May 2026 | 8 May 2026 |
| June | 19 June 2026 | 5 June 2026 |
| July | 24 July 2026 | 10 July 2026 |
| August | 21 August 2026 | 7 August 2026 |
| September | 18 September 2026 | 4 September 2026 |
| October | 23 October 2026 | 9 October 2026 |
| November | 20 November 2026 | 6 November 2026 |
| December | 18 December 2026 | 4 December 2026 |
| Month | Meeting Date (subject to change) | Submission Date |
|---|---|---|
| January | 24 January 2025 | 10 January 2025 |
| February | 21 February 2025 | 7 February 2025 |
| March | 21 March 2025 | 7 March 2025 |
| April | 25 April 2025 | 10 April 2025 |
| May | 23 May 2025 | 9 May 2025 |
| June | 20 June 2025 | 6 June 2025 |
| July | 25 July 2025 | 10 July 2025 |
| August | 22 August 2025 | 8 August 2025 |
| September | 26 September 2025 | 10 September 2025 |
| October | 24 October 2025 | 10 October 2025 |
| November | 21 November 2025 | 7 November 2025 |
| December | 26 December 2025 | 10 December 2025 |
| Month | Meeting Date (subject to change) | Submission Date |
|---|---|---|
| December | 27 December 2024 | 10 December 2024 |
注意事项
BH-IEC Secretariat
